Phenprocoumon
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
(RS)-4-hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one | |
| Clinical data | |
| Trade names | Marcoumar, Marcumar, Falithrom |
| AHFS/Drugs.com | International Drug Names |
| MedlinePlus | a699003 |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 99% |
| Metabolism | hepatic to inactive metabolites |
| Biological half-life | 5 to 6 days |
| Identifiers | |
| CAS Number |
435-97-2 |
| ATC code | B01AA04 (WHO) |
| PubChem | CID 9908 |
| IUPHAR/BPS | 6839 |
| DrugBank |
DB00946 |
| ChemSpider |
10441592 |
| UNII |
Q08SIO485D |
| KEGG |
D05457 |
| ChEBI |
CHEBI:50438 |
| ChEMBL |
CHEMBL1465 |
| Chemical data | |
| Formula | C18H16O3 |
| Molar mass | 280.318 g/mol |
| |
| |
| (verify) | |
Phenprocoumon (marketed under the brand names Marcoumar, Marcumar and Falithrom) is a long-acting oral anticoagulant drug, a derivative of coumarin. It is a vitamin K antagonist that inhibits coagulation by blocking synthesis of coagulation factors II, VII, IX and X. It is used for the prophylaxis and treatment of thromboembolic disorders (thrombosis/pulmonary embolism). It is the standard coumarin used in Germany.
Phenprocoumon is a 4-hydroxycoumarin and inhibits vitamin K epoxide reductase.[1]
References
- ↑ Phenprocoumon at PharmGKB
External links
| ||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
